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Abstract
Background: Clinical applicability of newly discovered reagents for molecular imaging is hampered by the lack of
translational models. As the dog prostate cancer (DPC-1) model recapitulates in dogs the natural history of prostate
cancer in man, we tested the feasibility of single-photon emission computed tomography (SPECT)/CT imaging in
this model using an anti-prostate-specific membrane antigen (PSMA)/17G1 antibody as the radiotracer.
Methods: Immunoblots and immunohistochemistry (IHC) with 17G1 were performed on canine and human
prostate cancer cell lines and tissues. Five dogs with DPC-1 tumors were enrolled for pelvic and, in some
instances, thoracic SPECT/CT procedures, also repeated over time. Controls included 111indium (In)-17G1 prior
to DPC-1 implantation and 111In-immunoglobulins (IgGs) prior to imaging with 111In-17G1 in dogs bearing
prostatic DPC-1 tumors.
Results: 17G1 cross-reactivity with canine PSMA (and J591) was confirmed by protein analyses on DPC-1, LNCaP, and
PC-3 cell lines and IHC of dog vs. human prostate tissue sections. 17G1 stained luminal cells and DPC-1 cancer cells in
dog prostates similarly to human luminal and cancer cells of patients and LNCaP xenografts. SPECT/CT imaging
revealed low uptake (≤2.1) of both 111In-17G1 in normal dog prostates and 111In-IgGs in growing DPC-1 prostate
tumors comparatively to 111In-17G1 uptake of 3.6 increasing up to 6.5 values in prostate with DPC-1 lesions. Images
showed a diffused pattern and, occasionally, a peripheral doughnut-shape-like pattern. Numerous sacro-iliac lymph
nodes and lung lesions were detected with contrast ratios of 5.2 and 3.0, respectively. The highest values were
observed in pelvic bones (11 and 19) of two dogs, next confirmed as PSMA-positive metastases.
Conclusions: This proof-of-concept PSMA-based SPECT/CT molecular imaging detecting primary prostate tumors and
metastases in canines with high cancer burden speaks in favor of this large model’s utility to facilitate technology
transfer to the clinic and accelerate applications of new tools and modalities for tumor staging in patients.
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Background
Prostate cancer (PCa) is the second most common
cause of cancer in men and among the leading causes of
death by cancer worldwide [1]. Modalities developed to
assess risk categories and select best therapeutic options
comprise digital rectal examination, levels of circulating
prostate-specific antigen (PSA), and Gleason score of
prostate biopsies (referred to as the D’Amico criteria)
[2, 3], also coupled to percentage of positive biopsies
and patient age (known as the UCSF-CAPRA score)
[4]. Local staging may be improved by multiparametric
magnetic resonance imaging (MRI) [5], although sensitiv-
ity to detect lymph node (LN) metastases remains low
(~40 %) [6]. Whole body diffusion MRI appears accurate
for detection of bone metastases [7], even if non-specific
and relying on differential vascularization and density of
benign vs. cancer tissues [5].
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Molecular imaging with radiotracers by single-photon
emission computed tomography (SPECT) and positron
emission tomography (PET) has opened a new era in
cancer staging by incorporating tumor cell biology
into the equation [8]. The discovery of prostate-
specific membrane antigen (PSMA) overexpression in
PCa [9–11] has paved the way to targeted rather than
functional imaging, as achieved by PET/CT with 18F-cho-
line uptake in proliferating PCa cells [12]. Among PSMA-
attractive features are prostate specificity for luminal
secretory cells with minimal expression in other tissues
and increasing levels from low grade to metastatic
castrate-resistant prostate cancer (CRPC) [9, 10].
Historically, PSMA-targeted molecular imaging was
achieved through 111indium (In)-labeled monoclonal
antibodies (mAbs) like 7E11 (first generation) and J591
(second generation) which permitted the detection of
necrotic tissue vs. LN and bone metastases due to the
recognition of intracellular vs. extracellular epitopes,
respectively [9, 10]. Recently, PET/CT with 89Zr-labeled
J591 has identified prostatic tumor foci in 8 of 11 (72 %)
patients prior to prostatectomy, although the standard-
ized uptake value did not correlate significantly with the
Gleason score [13]. To counter the slow elimination of
full-length mAbs from circulation and also optimize
tumor contrast, PSMA derivatives were developed, not-
ably radiolabeled minibodies (diabody/J591 mAb), small
molecule inhibitors (MIP1072, MIP1095), and ligands
[10, 14–19]. Utility in clinical practice is being demon-
strated; for instance, PET/MRI with 68Ga-based PSMA
ligands revealed LN and bone metastases in patients
with progressive disease after conventional treatments
[16]. The inhibitor MIP1095 showed utility for PET/CT
target imaging once labeled with 124I (iodine) and also
tumor therapy in CRPC patients once labeled with 131I
[19]. These observations highlight molecular imaging as
a promising avenue to better stage and treat patients
with locally advanced and recurrent PCa.
A major limitation for testing new modalities is the
lack of suitable translational models. Of relevance is the
unique propensity of the canine species, unlike most
mammals, to spontaneously develop PCa with advancing
age, although to a lesser frequency than human [20].
Interestingly, PCa in canines mimics the advanced form
of the human disease characterized by a high tumor bur-
den and the presence of numerous local and distant me-
tastases, notably to the skeleton [20]. Our team has
developed [21] and optimized [22] an orthotopic dog
prostate carcinoma (DPC-1) model that recapitulates
the advanced form of PCa in dogs. In the present
investigation, we obtained proof of concept of the
reliability of this model for molecular imaging by
SPECT/CT using an 111In-labeled mouse mAb (17G1)
targeting human PSMA [23].
Methods
Antibody production
The generation of anti-PSMA mAbs or 17G1 was de-
tailed elsewhere [23]. Briefly, 17G1 is a murine IgG1k
monoclonal antibody obtained by immunizing BALB/c
mice with a peptide (490Nt-GKSLYESWTKK) derived
from the human PSMA extracellular amino acid
sequence conjugated to keyhole limpet hemocyanin. The
antibody was purified from the supernatant of hybrid-
oma cell culture media by affinity chromatography using
a HiTrap protein G column, as per manufacturer’s
instructions (GE Healthcare Life Sciences, PA, USA),
concentrated to ~1–5 mg proteins per milliliter by ultra-
filtration (Millipore, ON, Canada) and stored at −20 °C
in 10 % glycerol. Purity was ascertained by Coomassie
staining of proteins separated by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE). The
17G1 specificity for human PSMA was reported [23]
with detection of the recombinant protein and a ~100-
kDa band in Western blots of PSMA-positive LNCaP
but not PSMA-negative (control) PC-3 [24]. The J591
mAb was similarly purified from the hybridoma obtained
from the American Type Culture Collection (ATCC,
MD, USA) and used for comparison purposes.
Prostate cancer cell lines
Cell lines, canine DPC-1 (patent US2003013191: Cussenot
and Villette, France), and human PC-3 (CRL-143) and
LNCaP (CRL-1740) (ATCC) were maintained in RPMI
1640 containing 10 % fetal bovine serum and 1 % anti-
biotic/antimycotic solution (Invitrogen Life Technologies,
Inc., ON, Canada).
Dot and Western blots and silver staining
Cells in monolayers were washed twice with ice-cold
phosphate-buffered saline (PBS), recovered by scraping,
and collected by low-speed centrifugation (1000×g,
10 min) prior to protein solubilization in RIPA buffer
(20 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 % Nonidet
P-40, 1 mM Na vanadate, 10 μg/ml aprotinin, 10 μg/ml
leupeptin). Lysates were clarified by centrifugation
(14,000×g, 5 min) and supernatants recovered to deter-
mine protein concentrations (BCA assays), using bovine
serum albumin (BSA) as the standard.
For dot blots, protein samples (1–4 μg) were directly
applied to nitrocellulose membranes and incubated in
5 % milk blocking solution in 1 % Tween in Tris-base
buffer saline (TTBS) for 60 min and then with 17G1 and
J591 (dilution 1:1000) in PBS for 2 h at room
temperature. Membranes were washed three times with
5 % milk TTBS, incubated for 60 min with secondary
mouse antibodies conjugated to peroxidase (1:3000;
Thermo Scientific, Il, USA), and washed again with
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TTBS to reveal reactivity with the enhanced chemilu-
minescence (ECL) reagent (Denville Scientific, NJ, USA).
For Western blotting, proteins (20 and 40 μg) were
separated by SDS-PAGE gel (4–15 % acrylamide gradi-
ent) and transferred onto nitrocellulose membranes (as
above for dot blots) for incubation with 17G1 and J591
(1:500 in milk TTBS, overnight at 4 °C). PSMA was also
immunoprecipitated (750 μg proteins) with 17G1 (2 μg)
overnight at 4 °C. Antigen:antibody complexes were
recovered by sepharose-G beads, washed three times
with PBS, and separated by SDS-PAGE. At this point,
proteins were either directly stained in gels with silver
nitrate, as per manufacturer’s instructions (Pierce® Silver
Stain, Thermo Scientific), or transferred to membranes
for Western blotting with 17G1 as above.
Immunofluorescence (IF) and immunohistochemistry (IHC)
Cells cultured on poly-L-Lysine-coated eight-well plastic
chambers were fixed with 3.7 % paraformaldehyde; prein-
cubated (5 min) with 50 mmol/l NH4Cl (10 min), 0.5 %
Triton X-100 in PBS, and 0.5 % BSA-PBS solution
(10 min), prior overnight incubation with 17G1 (1:250 in
BSA); and revealed by mouse secondary antibodies,
coupled to rhodamine (CY3; Invitrogen Life Technologies,
Inc.), as described in [25]. Nuclei were counterstained
with 4,6-diamidino-2-phenylindole (DAPI) (Life Tech-
nologies Inc., Burlington, Canada) and analyzed by
microscopy (Olympus IX81).
For immunohistochemistry (IHC), sections (4 μm)
from formaldehyde-fixed paraffin-embedded blocks of
LNCaP s.c. xenografts grown in mice [26], dog prostates,
DPC-1 tumors, or other dog-harvested tissues [22], as
well as archival human prostate specimens, were stained
with 17G1, using the EnVision kit (DAKO, ON, Canada).
Unless indicated, incubations were performed at room
temperature. Steps included are as follows: rehydration
with graded alcohol, permeabilization with 1 % Triton
X-100/PBS (30 min), antigen retrieval with 0.01 M
sodium citrate buffer, pH 6.0 (15 min, 95 °C), quenching
of endogenous peroxidase activity with 3 % H2O2
(30 min), and non-specific staining with a blocking re-
agent (30 min; Millipore). After three washes (5 min,
PBS), sections were next incubated overnight at 4 °C
with 17G1 (1:200) in PBS containing 1 % blocking solu-
tion. After three more washes, biotinylated secondary
Abs (goat anti-mouse IgGs) and streptavidin-peroxidase
conjugate were added to amplify the signal. The reaction
was revealed within 1 min after the addition of chromo-
gen, 0.006 % 3,3′-diaminobenzidine tetrahydrochloride.
Sections were counterstained with hematoxylin, dehy-
drated, and mounted. Negative controls included sec-
tions incubated without 17G1. The staining was assessed
by two independent observers blind to the identity of
the sections. A consensus was reached on positive or
negative signals and cellular/tissue distribution. Images
were acquired using an Olympus microscope (IX81).
Implantation of DPC-1 cells
Intact mongrel dogs (n = 5; Laka, Montréal, QC, Canada)
of different breeds, body sizes (25–38 kg), and age
(≥5 years old) were individually housed within animal
facilities certified for Good Animal Practice care by the
Canadian Council on Animal Care. They were fed a
regular canine diet (except the night before surgery) and
had free access to water. Conditions to implant DPC-1
cells within the prostate and follow tumor development
over time were as depicted earlier [22]. Prostate biopsies
(transabdominal ultrasound-guided approach) were
positive by ~6–8 weeks.
Conjugation and radiolabeling of 17G1
All solutions were prepared with deionized water
(Thermo Fisher Scientific) and treated with a Chelex-
100 resin, prewashed in 0.5 M sodium acetate pH 6.3
(Bio-Rad; Laboratories; CA, USA) to remove traces of
metal ions. To covalently conjugate 17G1 (or mouse
IgGs) to 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraa-
cetic acid (DOTA), the mAb buffer was replaced by
0.1 M sodium carbonate, pH 9.0, by overnight dialysis
(Spectrum Laboratories; CA, USA) or centrifugal ultra-
filtration (Millipore) at 4 °C. The 17G1 solution (1–5 mg
proteins per milliliter) was mixed with 50 molar excess
of DOTA-NHS-Ester (Macrocyclics, TX, USA) solubi-
lized in dimethylformamide at 35 mg/ml and incubated
for 30 min (at room temperature). The 17G1-DOTA
conjugate was immediately separated from unconjugated
DOTA-NHS-Ester and other chemicals by repeated
centrifugal ultrafiltration and a final wash with 0.3 M
ammonium acetate, pH 5.0. The protein concentration
of conjugated 17G1 was measured with the Pierce
Coomassie Plus kit (Thermo Fisher Scientific).
The number of DOTA molecules linked to 17G1 was
determined by MALDI-TOFF mass spectrometry analysis.
A mass shift of 2436 Da (compared to unconjugated Ab)
confirmed the successful addition of DOTA (646.4 Da), at
~3.7 chelate molecules per 17G1 molecule. At this
17G1:chelate ratio, the 17G1-DOTA reactivity was com-
parable to 17G1 alone, as measured by ELISA.
Radiolabeling of 17G1 (or IgGs)-DOTA conjugates
was carried out no more than 2 days before injection.
Briefly, the 17G1-DOTA was mixed with 1–4 mCi of
111In-Chloride (Nordion, ON, Canada) in 0.01 M HCl
per milligram of mAb and incubated at 43 °C for
60 min. The radiolabeled mAb was washed repeatedly
(three times) with PBS by centrifugal ultrafiltration to
remove unincorporated radionuclide. The protein con-
centration was measured (Bradford assays).
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Radiochemical purity was determined using 3 μl of
111In-DOTA-17G1 (or 111In-DOTA-mAb-IgGs), which
was incubated for 15 min with an equivalent volume of
1 % diethylene triamine pentaacetic acid (DTPA), pH 5.5,
to chelate residual free 111In. An aliquot was submitted to
thin layer chromatography (10-cm silica-gel-impregnated
glass fiber strip; TLC-SG, Agilent; CA, USA) developed in
1 % DTPA, pH 5.5. When the solvent front reached the
top, the strip was cut to count the radioactivity (gamma
counter) of 17G1-DOTA at the origin and unbound 111In
at the solvent front.
SPECT/CT imaging
Procedures were carried out in each animal (n = 5) as a
function of enrolment (time 0) with follow-up in months
(Additional file 1: Figure S1). At the time of injection,
the specific 111In-17G1 (or control 111In-IgGs) radio-
activity ranged from 0.9 to 4.5 mCi/mg (mean of
2.6 mCi/mg) with less than 2 % free 111In. Most dogs
had more than one SPECT/CT session with 111In-
DOTA-17G1 (several weeks apart). Two animals had
additional imaging with 111In-DOTA-IgGs.
The 111In-DOTA-17G1 (or radiolabeled IgGs) was
injected in bolus through an i.v. saline line in a front leg
at a total mean dose of 0.037 mg mAbs (0.023–
0.104 mg) per kilogram. Unless otherwise indicated,
SPECT/CT was performed 2 days later. Pelvic and, in
some instances, thoracic imaging were carried out in the
same session. The bladder was flushed with saline using
a urinary catheter before image acquisition and main-
tained during procedures to minimize bladder uptake
and obtain clearer images of the lower urinary tract.
Beside areas of interest, the radiotracer was seen in the
liver, heart, and salivary glands in agreement with the
literature [9]. Subsequent urine analysis by gel filtration
revealed only free 111In. Experimental end points ranged
from 2 to 5 months.
Pharmacokinetics
Blood was sampled in anticoagulant tubes to perform
17G1 pharmacokinetics prior to and over time post-
injection (5, 15, 30 min and daily up to 10 days). Specimens
were kept at 4 °C during sampling and next centrifuged to
measure plasmatic 17G1 using a mouse IgG ELISA kit
(Roche Life Science, IN, USA).
Image analysis
Images were obtained with an Infinia Hawkeye4 Hybrid
GE camera. SPECT/CT data were analyzed with a clin-
ical workstation (Segami OASIS, Segami Corp, USA).
Images were reconstructed using OSEM3D algorithm
with CT attenuation correction (hybrid reconstruction, 4
iterations, 10 subsets). Lesion location, size, and signal
(S) to background (B) ratio (S/B) were noted for every
lesion judged abnormal either on CT or SPECT. Scans
were read chronologically for all animals. Readers were
blinded to the presence of tumors and injected radio-
tracers (111In-17G1 vs. 111In-IgGs) at different time points.
Histopathology
Euthanasia (90 mg pentobarbital per kilogram i.v.) was
induced under anesthesia 1 week after the last SPECT/
CT imaging. The abdominal, pelvic, and thoracic cavities
were inspected by the veterinary pathologist (ES). The
prostate, bladder, and adjacent tissues like the iliosacral
lymph center (medial iliac, internal iliac, and sacral LNs)
were collected en bloc as well as lungs with visible
metastases and suspicious pelvic bone segments. The
prostate was weighed, measured, and inked prior to fix-
ation in 10 % buffered formaldehyde. In some instances,
lung metastases of varying size were dissected on ice,
weighed, and counted to assess remaining radioactivity.
The fixed prostate was cut from the cranial to caudal
(3–5-mm-thick slices with central urethra) for paraffin-
embedding. Whole-mounted sectioning (4 μm) of blocks
allowed an overall appreciation of DPC-1 tumor foci
once stained with hematoxylin and eosin (H&E) and ex-
pression of PSMA through IHC with 17G1, as described
above. Other tissues were similarly processed. The time
of fixation was extended to 48 h for bone segments, next
decalcified in 5 % nitric acid until softness, and paraffin-
embedded [22].
Results
17G1 cross-reacts with canine PSMA
PSMA protein sequences in human and canine are highly
homologous [27], notably in the amino acid sequence
490–500 of the human peptide (GKSLYESWTKK) used to
generate 17G1 [23] compared to the equivalent canine
amino acid sequence (GKSLYESWNEK). Accordingly, the
reactivity of 17G1 towards canine PSMA was ascertained
and compared to J591. Dot blots (Fig. 1a) illustrate a
strong signal of both mAbs on DPC-1 and LNCaP (posi-
tive control) and no reactivity on PC-3 proteins (negative
control) [23, 24] (despite increasing quantities). No signal
was detected using mouse IgGs (not shown). In Western
blots, 17G1 detected a ~100-kDa band in LNCaP cell ex-
tracts but no band in DPC-1 and PC-3, in agreement with
earlier reports [23, 24]. Similarly, Western blots with J591
yielded a positive signal only in LNCaP (data not shown).
The possibility that 17G1 recognizes the native PSMA
protein in DPC-1 cells was explored by immunoprecipi-
tation with 17G1, followed by SDS-PAGE gels and silver
staining of proteins. Results confirmed the presence of a
silver-stained ~100-kDa band in both LNCaP and DPC-1
(Fig. 1a), whereas reprobing immunoprecipitated PSMA
with 17G1 only led to a signal at ~100 kDa in LNCaP
(data not shown). Altogether, these findings support the
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recognition of a conformational epitope by 17G1 in
the native canine PSMA protein. PSMA expression in
DPC-1 cells was also confirmed by immunofluores-
cence (Fig. 1a) while there was no signal with control
IgGs (data not shown).
In IHC (Fig. 1b), 17G1 was highly specific for the
epithelium, staining luminal cells in dog, and human
benign prostates and cancer cells in prostate tumors
from patients, DPC-1 prostate tumor in dogs, and
LNCaP xenografts. The 17G1-PSMA reactivity was
particularly concentrated at the apical membrane of the
secretory epithelium of the canine prostate. Yet, some
cytoplasmic reactivity was occasionally observed. The
signal was cytoplasmic in luminal cells of the human be-
nign prostate although the apical pole may occasionally
be stained. A comparable signal was detected in prostate
tumor cells, human (patients and LNCaP) and canine
(DPC-1-derived).
Endothelial cells of blood vessels were negative in tis-
sues examined, both canine (normal and DPC-1 tumors)
and human (benign and cancer) prostates (Fig. 1b).
SPECT/CT imaging with 111In-17G1 detects prostatic tumors
The optimal time for image acquisition of 111In-17G1 in
the prostate was first assessed. The determination of the
S/B ratio over time (Fig. 2, top panel), with no significant
improvement at 72 or 96 h compared to 48 h; the half-life
of circulating 17G1 of 43.8 h, a time period indicating a
rapid elimination and significantly reduced bioavailability
at the latest time points (Fig. 2, lower panel); and the
2.8-day 111In half-life decay justified the choice of the
48-h time point as being optimal for further imaging.
Specificity was ascertained in two dogs (see Additional
file 1: Figure S1, experimental procedures). Negative
controls included are as follows: first, the 111In-17G1
antibody uptake in the prostate prior to DPC-1 cell im-
plantation, which was minimal (Fig. 3a), with a mean S/B
ratio of 1.65 (dog #1, 1.4; dog #2, 1.9). Second, in the same
dogs with biopsy-proven intra-prostatic DPC-1 tumors,
the mean S/B of 111In-mouse IgGs in the prostate deter-
mined at 4 months post-implantation was 2.1 (dog #1, 1.7;
dog #2, 2.6) (Fig. 3a). The S/B threshold for significance
was then arbitrarily fixed at 3.0, a ratio which can be
visually perceptible as positive in clinical practice. The
subsequent injection of 111In-17G1 nearly 2 weeks later
(Fig. 3a) yielded a mean prostate S/B of 4.5 (dog #1, 3.6;
dog #2, 5.3). The maximal 17G1 radiotracer uptake for the
five dogs was 6.5 (Fig. 3a), and for four dogs imaged more
than once, the specific uptake increased or remained the
same over time (except dog #1), a finding in support of
tumor growth.
Representative SPECT/CT fusion images of the
111In-17G1 uptake in the prostate (Fig. 3b) revealed a
diffused signal localized within the anterior two third
region of the gland. Serial whole-mount prostate sections
confirmed the presence of several tumor foci at histopath-
ology, which could account for the observed tracer uptake
pattern (Fig. 3b). In one instance (dog #1), the radiotracer
(See figure on previous page.)
Fig. 1 17G1 cross-reactivity with canine PSMA. a Protein extracts of PCa cell lines, human (PC-3 and LNCaP) and canine (DPC-1), probed with
17G1 and J591 in dot (top left) and Western (top middle) blots and also submitted to immunoprecipitation of PSMA in DPC-1 and LNCaP protein
extracts and SDS-PAGE gels to stain proteins with silver nitrate (top right). Arrow indicates the PSMA position at ~100 kDa. PSMA expression in
DPC-1 cells, as detected by immunofluorescence (IF) with 17G1 (red staining; lower left) and DAPI nuclear staining (in blue; lower right). b PSMA
expression by IHC with 17G1 in the canine prostate (top left) and primary DPC-1 tumor (top right), human LNCaP tumor xenograft (lower left),
benign human prostate (lower middle), and PCa tissue (lower right). Arrow indicates unstained endothelial cells
Fig. 2 Timing for 17G1 imaging and pharmacokinetics. The radiotracer
(111In-17G1) was injected as described in the “Methods” section. A first
SPECT/CT imaging of the prostate was performed after 48 h and then
daily for two more days (top panel). Lesion-to-background ratio was
determined and plotted (top panel). Blood was sampled from prior to
and over time post-injection till 10 days and processed to determine
the plasma concentration of 17G1 as mentioned in the “Methods”
section, plotted as the logarithmic 17G1 concentration vs. time (lower
panel) and fitted to a straight line (R2 = 0.99) to calculate the
half-life elimination
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uptake displayed a doughnut-shaped more peripheral
pattern (Fig. 3c), which was mirrored histopathologic-
ally by tumor foci reaching the capsule and beyond.
Indeed, after 4–5 months post-DPC-1 implantation,
extraprostatic extension was a common feature to all
dogs (not shown). Finally, PSMA expression in DPC-1
tumors was confirmed by IHC with 17G1. An ex-
ample of tumor foci at the periphery of the prostate
with diffused cytoplasmic staining is shown (Fig. 3c).
With the prostate weight varying from 8 to 47 g, the
tumor load may represent a significant volume in this
model.
SPECT/CT imaging with 111In-17G1 detects LN metastases
Several foci of tracer uptake in the pelvic area of dogs
harboring DPC-1 tumors (Fig. 4) were observed in
fusion images and next ascribed to enlarged sacro-iliac
LN metastases detectable with 17G1 in each dog at the
first imaging session, the earliest being at 2 months
post-implantation. A representative example of imaged
LN lesions in dog #1 at ~19 weeks is included (Fig. 4);
the radiotracer uptake varied slightly with LN size
although the correlation was very weak (R2 = 0.03) and
not significant. The uptake even decreased over time
when LNs became larger and necrotic.
The mean S/B ratio in LNs was 5.2 ± 2.1, and the
average size of detected LN lesions was 2.7 ± 1.2 cm.
The smallest LN was of ~1 cm, with a S/B ratio of 2.5.
At necropsy, enlarged sacro-iliac LNs of varying sizes
were collected, the largest ones being often necrotic in
line with imaging results. In IHC, DPC-1 tumor cells in
LNs were 17G1-positive with a diffused cytoplasmic
(See figure on previous page.)
Fig. 3 Specificity of prostate imaging with 111In-17G1. a Tracer uptake in the prostate. Dogs #1 and #2 served as controls to establish a threshold
for significance. 111In-17G1 was injected prior to DPC-1 cells implantation and at 4.5 months of tumor growth (biopsy-proven between 6 and
8 weeks) along with 111In-mouse IgGs at 4 months. b Representative SPECT/CT axial, sagittal, and coronal images of 111In-17G1 uptake (top) in a
large portion of the prostate of dog #5 and corresponding tumor foci mapped in sections from consecutive whole-mounted blocks (lower).
c Example of SPECT/CT image with 111In-17G1 uptake in the periphery of the prostate (left top), confirmed by mapping DPC-1 tumor foci at the
capsule (lower panel), PSMA expression by IHC (middle top) and corresponding H&E staining (right top) ×20
Fig. 4 SPECT/CT imaging with 111In-17G1 reveals lesions in LNs. Pelvic scan showing sacro-iliac LNs by CT (left) with radiotracer uptake (middle)
and fusion SPECT/CT image (right). The radiotracer to background uptake measured in several LNs weakly correlated with size (lower panel)
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signal (Additional file 2: Figure S2). Some reactivity was
also observed in the cell debris of necrotic LNs.
SPECT/CT imaging of DPC-1 lung nodules with 111In-17G1
Considering the high incidence rate of prostate-derived
lung nodules in dogs with spontaneous prostate cancer
[28, 29] and the DPC-1 model [22], thoracic SPECT/CT
imaging was performed in three dogs (#3–5). A repre-
sentative fusion image revealing the radiotracer uptake
in several lesions is shown (Fig. 5a). The specific radio-
tracer uptake correlated significantly with the size of
pulmonary nodules (R2 = 0.85), with an average S/B ratio
of 3.0 ± 1.7 (1–5.5) (Fig. 5, top middle; dog #1 at
24 weeks). The smallest SPECT/CT detected lung
nodules measured 1.4 ± 0.5 cm (0.8–2.4 cm), although
smaller lesions were anatomically visible on CT (Fig. 5a).
Pulmonary nodules excised 5 days after the last
imaging session still contained significant residual radio-
tracer (111In-) (Fig. 5b), which correlated linearly with
their size (R2 = 0.84); counts ranged from 1700 cpm for a
30-mg nodule to 65,800 cpm for a 1.9-g nodule. The
abundance of lung nodules (greater than 200) set the
tumor volume at a very high level. DPC-1 cells of lung
metastases strongly expressed PSMA (Fig. 5b).
SPECT/CT imaging with 111In-17G1 detects DPC-1 bone
metastases
Bone metastases are a common feature of spontan-
eous PCa in dogs [28–30] and also observed in the
DPC-1 model [22]. SPECT/CT pelvic images were
further analyzed for the presence of 111In-17G1 tracer
in bone segments (Fig. 6). A remarkably high uptake
was detected in an obturator bone of dog #3 and iliac
bone of dog #5 at 4 months post-DPC-1 cell implant-
ation, with S/B ratios of 11.6 and 19.0, respectively.
DPC-1 cells in metastatic bones were confirmed to
strongly express PSMA (Fig. 6).
Discussion
This investigation is the first of its kind demonstrating
that prostate tumors and associated metastases can be
successfully detected by molecular imaging in the ortho-
topic DPC-1 model recapitulating in large dogs the
advanced form of human PCa [21, 22]. PSMA was a rea-
sonable target to choose in this proof-of-concept study
given its reported expression in DPC-1 tumors [21] and
confirmed in this study. We selected the 17G1 mAb [23]
for imaging as it was raised against a human PSMA
peptide highly homologous to the corresponding peptide
sequence in canine PSMA [23, 27]. Moreover and simi-
larly to J591, 17G1 recognizes the human PSMA protein,
recombinant and as a ~100-kDa band in LNCaP.
Consistently, cross-reactivity and specificity of 17G1
with canine PSMA were confirmed by different means:
(1) dot blots with DPC-1 and LNCaP but not PC-3 pro-
teins yielded a strong reactivity, in agreement with the
literature [31]; (2) 17G1 immunoprecipitated a DPC-1
and LNCaP silver-stained band migrating at ~100 kDa
in SDS-PAGE gels; and finally, (3) a similar band was de-
tected by 17G1 in Western blots of LNCaP proteins but
not DPC-1, thus strongly supporting the recognition of
the native protein in both cell lines along with the dena-
tured protein in LNCaP. Yet, PSMA was reported to be
a ~100–110-kDa glycoprotein in LNCaP, consisting of a
84-kDa protein moiety predicted from the cDNA and
carbohydrates accounting for 20–25 % of its mass [32].
The reported homology between the human and canine
protein sequence (82 % identity) [27] together with our
findings of a similar protein band in LNCaP and DPC-1
suggest comparable glycosylation patterns. Nonetheless,
the fact that 17G1 recognized native forms of PSMA is
most valuable in the context of molecular imaging
whereby intravenously injected radiotracers recognize
accessible epitopes in native proteins.
An observation supporting the use of 111In-17G1 as a
pharmaceutical for SPECT/CT imaging was 17G1’s spe-
cificity for adenocarcinoma cells in IHC, with a diffused
cytoplasmic and membrane staining pattern in cancer
cells of DPC-1, patients’ prostate tumors, and LNCaP
xenografts. However, the strong 17G1 staining of PSMA
in luminal/secretory cells of the normal dog and human
(benign) prostates, as reported in [33], might have been
a disadvantage to image intra-prostatic tumors. Yet, the
inclusion of controls permitted to discriminate specific
from non-specific radiotracer uptake. Despite the slow
clearance of mAbs from circulation and tissues [10], a
2-day period between radiotracer injection and im-
aging was sufficient to minimize non-specific tracer accu-
mulation in most tissues except for the liver and bowel.
The first control—111In-17G1—injected prior to DPC-1
cell implantation led to a mean radiotracer prostatic accu-
mulation of 1.6 relative to background. The subsequent
control—111In-radiolabeled IgGs—injected in the same
dogs at 4 months from the time of DPC-1 cell implant-
ation (biopsy-proven tumors) led to a mean 2.1 S/B ratio.
Based on these values, a threshold of 3.0:1.0 was arbitrarily
chosen to define specific tracer uptake, a value visually
perceptible as positive in the clinic. Subsequent SPECT/
CT sessions (nearly 2-week interval after control IgGs)
validated this definition since the 111In-17G1 prostatic
uptake was then more than twofold higher than controls
with a mean prostate-to-background ratio of 4.5. More-
over, sequential imaging sessions in four of the five
enrolled dogs indicated increasing prostatic uptake over
time to a plateau in three dogs and subsequent decrease
in one, likely due to necrosis often seen in large tumor
foci. While it seems paradoxical that the elevated PSMA
expression (observed in IHC) in the normal canine
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Fig. 5 (See legend on next page.)
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prostate epithelium did not translate in a high radiotracer
uptake, a possible explanation may be a non-accessibility
of the antigen, an extracellular epitope of native PSMA, to
circulating 17G1 in the normal vs. malignant prostate. For
instance, the PSMA protein is particularly concentrated in
the apical pole of secretory cells opening onto the acinar
lumen of glands. The underlining basal cell layer and
basement membrane could represent a barrier separ-
ating PSMA-expressing luminal cells from blood
vessels in the stroma. Conversely, the loss of glandu-
lar architecture and a single cell layer remaining in
tumors, together with the loosening of the basement
membrane, could allow 17G1 to reach cancer cells.
This is supported by the low and high radiotracer
prostatic uptake, normal (S/B = 1.6) vs. malignant (S/B
up to 6.5), respectively, and organs with proven DPC-
1 tumors. As such, the reactivity of an antigen PSMA
at the tumor cell surface, with an antibody-circulating
radiotracer, implies the accessibility of native mole-
cules to each other. Whether PSMA and 17G1 leak
from their respective compartments is not known.
Nonetheless, as eluted to, in molecular imaging, 17G1
would bind PSMA in its native conformation.
Our study revealed two SPECT/CT uptake patterns in
prostate tumors, one generally diffused and a more
peripheral with a doughnut-shaped aspect. Microscopic
analyses of prostates were compatible with such pat-
terns, as several tumor foci were dispersed throughout
the prostate and beyond the capsule. These findings of
molecular imaging were corroborated by the PSMA
positivity of tumor cells and metastases, as shown by
IHC. Thus, despite the known limited intrinsic reso-
lution of SPECT images (human scanner of medium size
animals), PSMA-based prostate imaging might detect
extra-capsular extension, a determining factor for the
ideal planning of therapeutic approaches. Our data
linked the signal intensity to prostate tumor growth over
time, found to be best achieved when the extent of
tumor necrosis was limited. This paradigm also applied
to pelvic LN metastases, which were often necrotic when
reaching the experimental end point and as seen in PET
scan studies of patients affected by a variety of cancers
(See figure on previous page.)
Fig. 5 SPECT/CT imaging with 111In-17G1 reveals lung metastases. a Thoracic scan showing DPC-1 lesions in lungs (top): CT (left) and radiotracer
uptake (middle) with fusion image (right). Numerous small lesions were visible with the 17G1 radiotracer by SPECT (lower left). Lesion contrast to
background plotted as a function of nodule size (lower right). b Lung metastases visible (top left) at necropsy performed 1 week after the last
SPECT/CT imaging session. Subset of metastases were dissected (top middle) and weighed to count remaining radioactivity; the radiotracer uptake
correlates with weight of metastases (lower left), in line with SPECT/CT imaging data. DPC-1 cells in lung metastases (H&E, top right) express high
PSMA levels (IHC, lower right) (×40).
Fig. 6 SPECT/CT imaging with 111In-17G1 reveals bone metastases. View of pelvic bone scan by CT (top left), radiotracer uptake (top middle), and
fused SPECT/CT (top right). DPC-1 cells in bone metastases (H&E, lower left) and 17G1 IHC staining for PSMA (lower right) (×40)
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[34, 35]. SPECT/CT of the dog pelvic area revealed mul-
tiple sites of uptake, measuring as low as 1 cm, or 2.7 ±
1.2 cm in average, as ascribed by CT to sacro-iliac
lymphadenopathies. The mean radiotracer uptake to
background ratio (5.2 ± 2.1) was within the range of
values obtained in prostate tumors. However, the signal
intensity and size of LN metastases were poorly corre-
lated (R2 = 0.03). Nonetheless, these findings are encour-
aging for future optimization given the low sensitivity
and specificity of CT or MRI, with a ~40 % detection
rate of pelvic LN metastases, based on the classic 1-cm
threshold size [6].
Lung metastases are abundant in canines with DPC-1
tumors [21, 22]. As expected, thoracic SPECT/CT
imaging with 17G1 revealed numerous small lung
lesions averaging 1.4 ± 0.5 cm, with a mean contrast-to-
background ratio of 3.0. Smaller lesions (PSMA+ in
IHC) were visible on CT but could not be detected when
merged with SPECT. This limitation—small lesions not
reaching an uptake level high enough to be visible in
SPECT—is ascribed to the partial volume effect of the
SPECT scanner. Hence, sequential imaging follow-up on
dogs having lesions under 1.4 cm demonstrated increas-
ing size with a higher level of tracer uptake, consistent
with the partial volume effect. The tracer uptake
strongly correlated with the size of imaged lesions, con-
firmed to be visible metastases (at necropsy) remaining
radioactive for several days post-imaging (111indium
counts correlating with size of metastases) and highly
expressing PSMA (IHC). Another remarkable obser-
vation was the detection in two animals of pelvic
bone metastases (confirmed by histology and ex-
pressing PSMA) with a particularly high 111In-17G1
uptake (11 and 19 over background), the highest of
all imaged DPC-1 tumors despite the reported low
permeability of mAbs in solid tumors and notably
bone metastases [17].
Overall, this proof-of-concept study is quite unique as
it has coupled PSMA-based SPECT/CT images to the
growth of DPC-1 prostatic tumors and metastases both
local and distant, then histopathologically confirmed and
showed to express the targeted PSMA/antigen in a time-
wise manner resembling the natural history of prostate
cancer. PSMA-based studies are primarily performed on
heterotopic xenografts in rodents bearing a relatively
low tumor volume [36] compared to canines. This is
particularly attractive as, in contrast to most mammalian
species, canines spontaneously develop prostate cancer
although at a low incidence rate with ageing [20, 29, 37].
Unfortunately, the cancer is generally advanced at
diagnosis and has reached the terminal stage [28–30].
The DPC-1 preclinical model would prove to be most
advantageous to enhance resolution or track down very
small lesions using newly developed radiopharmaceuticals
(diabodies, minibodies, small molecule inhibitors), im-
aging tools (PET/CT, PET/MRI vs. SPECT/CT), etc. It
may find substantial utility to test new drugs or thera-
peutic modalities to destroy a high tumor/metastasis load
not achievable in small rodent models. Finally, the use of
equipment from the clinical setting in large size animals
is attractive and could accelerate applicability of new
devices prior moving to patients and impact on
disease from time of early diagnosis to late stages.
Conclusions
This proof-of-concept study confirmed the reliability of
the DPC-1 orthotopic model for molecular imaging and
recapitulating in large dogs the advanced form of human
disease. Tumors are detectable within the prostate and
at the capsule along with pelvic lymph nodes and distant
lung and osseous metastases. As the tumor load is
significant in volume, this model may serve for the
development of a wide spectrum of new staging and
therapeutic applications.
Additional files
Additional file 1: Figure S1. Timeline of experimental procedures.
Schematic illustration of imaging procedures performed with 17G1 and
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as a function of time following DPC-1 cell implantation in the prostate.
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with largest ones being often necrotic (lower left). IHC with 17G1
confirmed PSMA expression in DPC-1 cells forming LN metastases (top
right) and remaining debris in necrotic ones (lower right) (×40).
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